SURGERY FOLLOWING NEOADJUVANT MPV CHEMOTHERAPY (MITOMYCIN, CISPLATIN, VINBLASTINE) IN LOCALLY ADVANCED (IIIA AND IIIB) NONSMALL CELL LUNG-CANCER

被引：7

作者：

CARRETTA, A

CHIESA, G

ZANNINI, P

VILLA, E

VERUSIO, C

FUMAGALLI, F

MELLONI, G

GROSSI, A

机构：

[1] Department of Cardiothoracic Surgery, San Raffaele Hospital, Milan, I-20132

[2] Department of Radiochemotherapy, San Raffaele Hospital, Milan, I-20132

来源：

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 1994年 / 8卷 / 09期

关键词：

NONSMALL CELL LUNG CANCER; STAGE III; NEOADJUVANT CHEMOTHERAPY; SURGERY;

D O I：

10.1016/1010-7940(94)90014-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

From November 1990 to August 1993, 32 patients with non-small cell lung cancer (NSCLC) entered a multimodality treatment study with neoadjuvant Mitomycin, Cisplatin and Vinblastine (MPV), surgery and radiotherapy at the San Raffaele Hospital in Milan, Italy. Neoadjuvant chemotherapy was performed on an outpatient basis. To date 23 patients (11 stage III a and 12 stage III b) have completed the chemotherapy treatment and are available for evaluation of response, toxicity, surgical eligibility and resection rate. The overall major response to MPV chemotherapy was 87%. The overall resection rate after major response to treatment was 60% (90% in stage III a and 17% in stage III b). After a median follow-up of 21 months (8-31) 17 patients are still alive (74%). Ten patients (83%) who had a complete resection are alive after a median follow-up of 23 months (21-30) and eight of them (66%) are in complete pathological remission. No treatment-related mortality was observed. The authors conclude that MPV is a highly effective neoadjuvant regimen for NSCLC and is feasible on an outpatient basis. Favorable resection rates can be obtained in stage III a patients. Stage III b patients can be downstaged and undergo complete resection. A longer follow-up is needed to assess the impact of this multimodality approach on long-term survival and to evaluate the role of adjuvant radiotherapy.

引用

页码：457 / 461

页数：5

共 24 条

[1] Burkes R.L., Ginsberg R.J., Shepherd F.A., Blackstein M.E., Goldberg M.E., Waters P.F., Patterson G.A., Todd T., Pearson F.G., Cooper J.D., Jones D., Lockwood G., Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresect-able non-small cell lung cancer: Results of the Toronto phase II trial, J Clin Oncol, 10, pp. 580-586, (1992)
[2] Carmack Holmes E., Treatment of stage II lung cancer (T1N1 and T2N1), Surg Clin North Am, 67, 5, pp. 945-949, (1987)
[3] Einhorn L.H., Neoadjuvant therapy of stage III non-small cell lung cancer, Ann Thorac Surg, 46, pp. 362-365, (1988)
[4] Faber L.P., Kittle C.F., Warren W.H., Bonomi P.D., Taylor S., Salitha R., Myung-Sook L., Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer, Ann Thorac Surg, 47, pp. 669-677, (1989)
[5] Gralla R.J., Kris M.G., Burke M.T., Kelsen D.P., Heelan R., The Influence of the Addition of Mitomycin to Vindesine plus Cisplatin in a Random-Assignment Trial in 120 Patients with NSCLC. (Abstract) Proc am Soc Clin Oncol, 5, (1986)
[6] Holmes E.C., Gail M., Surgical adjuvant therapy for stage II and III adenocarcinoma and large cell undifferentiated carcinoma, J Clin Oncol, 4, pp. 710-715, (1986)
[7] Martini N., Beattie E.J., Results of surgical treatment in stage I lung cancer, J Thorac Cardiovasc Surg, 74, pp. 499-505, (1977)
[8] Martini N., Flehinger B.J., The role of surgery in N2 lung cancer, Surg Clin North Am, 67, 5, pp. 1037-1049, (1987)
[9] Martini N., Flehinger B.J., Zaman M.B., Beattie E.J., Results of resection in non-oat cell carcinoma with mediastinal lymph node metastases, Ann Surg, 198, pp. 386-397, (1983)
[10] Martini N., Kris M.G., Gralla R.J., Bains M.S., Mc Cormack P.M., Kaiser L.R., Burt M.E., Zaman M.B., The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2M0), Ann Thorac Surg, 45, pp. 370-379, (1988)

← 1 2 3 →